Skip to main content
. 2021 May 13;137(19):2634–2645. doi: 10.1182/blood.2020007512

Figure 3.

Figure 3.

DOR to loncastuximab tesirine, PFS, and OS. DOR by B-NHL subtype (A), for patients with DLBCL by dose (B), and for patients with DLBCL by response (C). (D) PFS for all patients with B-NHL and those with DLBCL, MCL, and FL. (E) OS for all patients with B-NHL and those with DLBCL, MCL, and FL.